BIM
PTGX icon

BlackRock Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

BlackRock Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$658K Buy
29,930
+1,032
+4% +$23K ﹤0.01% 2933
2016
Q3 		$611K Buy
+28,898
New +$395K ﹤0.01% 2940

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's PTGX Position: Q4 2016 in Review

BlackRock Investment Management increased its Protagonist Therapeutics (PTGX) stake by 3.6% in Q4 2016, buying an estimated $23K and bringing the position to 29,930 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #2933.

BlackRock Investment Management first reported a position in PTGX in Q3 2016 and has held it in 2 quarters since. 38 funds tracked by Wall St. Rank hold PTGX as of Q4 2016.

  • BlackRock Investment Management held 29,930 shares of Protagonist Therapeutics worth $658K as of Q4 2016.
  • BlackRock Investment Management bought 1,032 Protagonist Therapeutics shares in Q4 2016, an estimated $23K.
  • Protagonist Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2933 holding.
  • BlackRock Investment Management first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 2 quarters since.
  • 38 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.